I believe the negative effect such orders may have is downward pressure on prices in the pharma sector, and Cencora being a distributor in this process could have some impact, and so this topic is ...

Shareholders might have noticed that Cencora, Inc. (NYSE:COR) filed its quarterly result this time last week. The early response was not positive, with shares down 3.1% to US$283 in the past week.

Shares of Cencora (COR) have been strong performers lately, with the stock up 11.2% over the past month. The stock hit a new 52-week high of $309.35 in the previous session. Cencora has gained 35. ...

Cencora (COR) came out with quarterly earnings ... of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry ...

Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a pharmaceutical sourcing and distribution company. With a market cap of approximately $54 billion, Cencora operates through the U.S ...

May 7 (Reuters) - U.S. drug distributor Cencora (COR.N), opens new tab raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Second Quarter ... quarter earnings call last year. Excluding the impact of the manufacturers' price adjustments, we saw solid ...

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal second-quarter profit of $717.9 million. On a per-share basis, the Conshohocken, Pennsylvania ...